Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 6, 2011, Pages

  Giannini, Silvia ^a   Falcinelli, Emanuela ^a   Bury, Loredana ^a   Guglielmini, Giuseppe ^a   Rossi, Roberta ^a   Momi, Stefania ^a   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherosclerosis; Bleeding time; Flow cytometry; Platelet activation

Indexed keywords

CD40 LIGAND; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLEEDING TIME; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN INJURY; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADULT; ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; CD40 LIGAND; CELL COMMUNICATION; CELLS, CULTURED; CHEMOKINE CCL2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-8; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION INHIBITORS; SKIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79958023705     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00467.2010     Document Type: Article

References (47)

1. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-Derived CD40L. The Switch-Hitting Player of Cardiovascular Disease. Circulation 106: 896-899, 2000.
2. André P, Prasad KSS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner D. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat Med 8: 247-252, 2002.
3. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324: 71-86, 2002.
4. Büchner K, Henn V, Gräfe M, de Boer OJ, Becker AE, Kroczek RA. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol 201: 288-295, 2003.
5. Chandler AB, Earhart AD, Speich HE, Kueter TJ, Hansen J, White MM, Jennings LK. Regulation of CD40L (CD154) and CD62P (Pselectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. Thromb Res 125: 44-52, 2010.
6. Ciferri S, Emiliani C, Guglielmini G, Orlacchio A, Nenci GG, Gresele P. Platelets release their lysosomal content in vivo in humans upon activation. Thromb Haemost 83: 157-164, 2000.
7. Cipollone F, Chiarelli F, Davì G, Ferri C, Desideri G, Fazia M, Iezzi A, Santilli F, Pini B, Cuccurullo C, Tumini S, del Ponte A, Santucci A, Cuccurullo F, Mezzetti A. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 48: 1216-1224, 2005.
8. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, Fazia M, Iezzi A, Cuccurullo C, Pini B, Bucci M, Santucci A, Cuccurullo F, Mezzetti A. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108: 2776-2782, 2003.
9. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davì G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia; effects of statin therapy. Circulation 106: 399-402, 2002.
10. Donnini D, Perrella G, Stel G, Ambesi-Impiombato FS, Curcio F. A new model of human aortic endothelial cells in vitro. Biochimie 82: 1107-1114, 2000.
11. Falcinelli E, Giannini S, Boschetti E, Gresele P. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. Br J Haematol 138: 221-230, 2007.
12. Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, Malincarne L, Gresele P. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 23: 589-596, 2009.
13. Garlichs CD, John S, Schmeiber A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104: 2395-2400, 2001.
14. Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger K, Langenbrink K, Page S, Neumeier D, Schomig A, Brand K. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intracellular adhesion molecule-1 on endothelial cells. Circulation 98: 1164-1171, 1998.
15. Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, Hennekens CH. Low-dose aspirin and infsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 340: 143-145, 1992.
16. Gerli R, Paolucci C, Gresele P, Bistoni O, Fiorucci S, Muscat C, Belia S, Bertotto A, Costantini V. Salicylates inhibit adhesion, and transmigration of T. lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood 92: 2389-2398, 1998.
17. Gresele P, Arnout J, Coene MC, Deckmyn H, Vermylen J. Leukotriene B4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells. Biochem Biophys Res Commun 137: 334-342, 1986.
18. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 80: 1435-1445, 1987.
19. Gresele P, Marzotti S, Guglielmini G, Momi S, Giannini S, Minuz P, Lucidi P, Bolli GB. Hyperglycemia-induced platelet activation in type 2 diabetes mellitus is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 33: 1262-1268, 2010.
20. Heeschen C, Dimmeler S, Hamm CW, Van Den Brand MJ. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 1104-1111, 2003.
21. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40L on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594, 1998.
22. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98: 1047-1054, 2001.
23. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-infcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12: 74-82, 2001.
24. Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man: effect of low dose of aspirin. Thromb Haemost 57: 62-66, 1987.
25. Kuliczkowski W, Kobusiak-Prokopowicz M, Prajs I, Karolko B, Mazurek W. Aspirin failure course during exercise and its connection with soluble CD40L. Thromb Res 119: 679-686, 2007.
26. Marx N, Imohof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107: 1954-1957, 2003.
27. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, Freedman JE. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96: 1365-1369, 2005.
28. 3) on platelets upregulates CD40L and triggers CD40L dependent matrix degradation by endothelial cells. Circulation 106: 2111-2117, 2002.
29. Melgarejo E, Medina MA, Sánchez-Jiménez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 41: 998-1001, 2009.
30. Michelson AD, Ellis PA, Barnard MR, Matic GB, Viles AF, Kestin AS. Down regulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate or an in vivo wound. Blood 77: 770-777, 1991.
31. Mody M, Lazarus AH, Semple JW, Freedman J. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfus Med 9: 147-154, 1999.
32. Mutin M, George F, Lesaule G, Sampol J. Reevaluation of trypsin-EDTA for endothelial cell detachment before flow cytometry analysis. Endothelium 4: 289-295, 1996.
33. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107: 1123-1128, 2003.
34. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105: 2849-2854, 2002.
35. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy infjects. Thromb Res 17: 317-327, 1980.
36. Prasad KSS, André P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signalling. Proc Natl Acad Sci USA 100: 12367-12371, 2003.
37. Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 298: E1072-E1075, 2010.
38. Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A, Ongini E, Semeraro N, Colucci M, Gresele P. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost 3: 2554-2562, 2005.
39. Santilli F, Dav- G, Basili S, Lattanzio S, Cavoni A, Guizzardi G, De Feudis L, Traisci G, Pettinella C, Paloscia L, Minuz P, Meneguzzi A, Ciabattoni G, Patrono C. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost 8: 914-922, 2010.
40. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 80: 1008-1014, 1998.
41. Stumpf C, Lehner C, Raaz D, Yilmaz A, Anger T, Daniel WG, Garlichs CD. Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. Heart 94: 65-69, 2008.
42. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103: 2248-2253, 2001.
43. Vezza R, Nenci GG, Gresele P. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. J Pharmacol Exp Ther 275: 1497-1505, 1995.
44. Weiss HJ, Lages B. Studies of thromboxane B2, platelet factor 4, and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb/IIIa, and storage granules. Blood 82: 481-490, 1993.
45. Welt FGP, Rogers SD, Zhang X, Ehlers R, Chen Z, Nannizzi-Alaimo L, Phillips DR, Simon DI. GPIIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv 61: 185-189, 2004.
46. Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K, Kyrle PA. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 19: 1757-1760, 1999.
47. Yacoub D, Hachem A, Théorêt JF, Gillis MA, Mourad W, Merhi Y. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol 30: 2424-2433, 2010.